Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co-administration with doxorubicin

B Desrues, H Léna, F Brichory, MP Ramirez, L Toujas, P Delaval and L Dazord

1Service de Pneumologie, Centre Hospitalier Régional et Universitaire, Hôpital Pontchaillou, 35033 Rennes-Cedex, France; 2Centre Régional de Lutte contre le Cancer, Rue Bataille Flandres Dunkerques, BP6279, 35062 Rennes, France; 3Laboratoire d’Anatomie Pathologique B, Centre Hospitalier Régional et Universitaire, Hôpital Pontchaillou, 35033 Rennes-Cedex, France.

Summary
The efficacy of radioimmunotherapy of tumours with radiolabelled monoclonal antibodies (MAbs) depends on the amount of antibody taken up by the tumour and on its intratumoral distribution. In the case of MAbs directed against intracellular antigens, increasing the permeability of the cytoplasmic membrane may augment the bioavailability of the antigen for the antibody. This raises the question whether the induction of tumour necrosis by chemotherapy can enhance the tumour uptake of radiolabelled monoclonal antibodies. In this work, the effect of doxorubicin on the biodistribution of Po66, an MAb directed against an intracellular antigen, was studied in nude mice grafted with the human non-small-cell lung carcinoma cell line SK-MES-1. After injection on day 0 of 125I-labelled Po66, tumour radioactivity increased up to days 3–5, and then remained unchanged to day 14. The combined administration of 125I-labelled Po66 with 8 mg kg⁻¹ doxorubicin, in two doses separated by 7 days, doubled the radioactivity retained by the tumour. Histological and historadiographic analysis showed, however, that the drug induced cellular damage. In the absence of doxorubicin, the accumulation of Po66 was restricted to some necrotic areas, whereas with doxorubicin the necrosis was more extensive and the antibody more evenly distributed. These results suggest that chemotherapy and immunoradiotreatment combined would enhance tumour uptake of radioisotope and promote more homogenous distribution of the radiolabelled MAb. This would promote eradication of the remaining drug-resistant cells in tumours.

Keywords: monoclonal antibody; lung carcinoma; tumour-bearing mouse model; doxorubicin

Monoclonal antibody-targeted radiotherapy relies on differential radioisotope uptake in tumour and tissues. This first requires that the amount of circulating radiolabelled monoclonal antibody (MAb) should be as low as possible to minimise non-specific irradiation of normal tissues. Second, the tumour uptake of MAb should be as elevated and long-lasting as possible to deliver sufficient radiation to the tumour.

Several techniques have been devised to overcome the non-specific irradiation due to persistence of the radiolabelled MAb in the circulation. Among these are the use of F(ab)² fragments, which are cleared rapidly from blood (Buchbaum et al., 1990; Sharkey et al., 1990), and the injection of a second antibody provoking the formation of immune complexes, which are rapidly eliminated from blood (Blumenthal et al., 1988). Unbound antibody can also be removed from the circulation by means of immunoadsorption (Lear et al., 1991). Non-specific irradiation should be minimised by the use of two-step MAb-targeting techniques, combining first the administration of bifunctional (Le Doussal et al., 1989; Bosslet et al., 1991) or pretargeted MAbs (streptavidylated or enzyme conjugated) (Kalafonos et al., 1990; Hawkins et al., 1993), and second the injection of hapten-, biotin- or substrate-bound radionuclides, which are rapidly cleared from blood.

The amount of MAb taken up by tumours depends on several biological parameters, such as molecular size, the specificity and affinity of the MAb, the amount and location of the antigen, as well as tumour size, vasculature and interstitial pressure (Jain, 1990) and the host response to foreign immunoglobulin (Reynolds et al., 1989). As a general rule, the proportion of MAb taken up by the tumour is low (0.001–0.1% of the injected dose in man), and distribution of MAbs within the tumours is heterogeneous. Accordingly, several techniques have been proposed to enhance the tumour uptake of MAbs. An increase in MAb affinity can enhance tumour uptake of MAbs (Schlom et al., 1992). The use of F(ab)² or Fab fragments improves penetration of tumours (Endo et al., 1988; Buchbaum et al., 1990; Sharkey et al., 1990). The amount of MAb injected can be increased until antigenic sites are saturated (Goodman et al., 1993). The use of several MAbs of different specificity, or recognising different epitopes of the same tumour-associated antigen (Buchegger et al., 1989), increases antibody uptake. It has also been proposed to increase tumour antigen expression with interferon (Rosenblum et al., 1988), or to modify tumoral vasculature with interleukin 2 (Nakamura et al., 1994) or interleukin 2 immunconjugate (LeBerthon et al., 1991) in order to improve the accessibility to tumour antigens.

With MAbs directed against intracellular antigens, the ability of the antibody to reach its target depends on tumour cell membrane permeability. The latter is increased at various stages of the cell degeneration process which occurs spontaneously in tumours, even at an early stage of their growth (Cooper et al., 1975). Tumour necrosis may be increased by chemotherapy. This results in enhanced accessibility of intracytoplasmic tumour antigens to MAbs. In this study, we used a tumour-bearing mouse model, to described the biodistribution of Po66, an MAb directed against a still unknown intracytoplasmic antigen present in non-small-cell lung carcinoma. We show that administration of doxorubicin enhances the uptake of 125I-radiolabelled Po66 by tumours and improves the homogeneity of the distribution of the MAb throughout the tumours.

Materials and methods

Production and radioiodination of monoclonal antibodies
MAb Po66, a mouse IgG1, was obtained as described previously (Dazord et al., 1987). Briefly, Balb/c mice were immunised with enzymatically dissociated cells from a patient's lung squamous cell carcinoma. Mouse immune cells were fused with SP2.0 plasmocytoma and MAb Po66 was selected from the hybrids obtained. Po66 consistently reacted with squamous cell carcinomas and half of the adenocarcinomas tested, but not with small-cell lung carcinoma. MAb
Po66 bound to a 47 kDa cytoplasmic glycoprotein (Martin et al., 1989). It did not recognise normal tissues except distal renal tubules and gastric and bronchial serous glands. The Po66 batch used in the present work was purified from ascites obtained from hybridoma i.p. grafted Balb/c mice. The ascites fluid was precipitated in 40% saturated ammonium sulphate, dialysed against 10 mM phosphate buffer, pH 8 and eluted from a DEAE ion-exchange column with 10–150 mM, pH 8 phosphate buffer gradient. A mouse monoclonal immunoglobulin, Py, without known specificity, was taken as control and processed like Po66. Samples of Po66 and Py were radioiodinated with iodine-125 by the iodiumen method and separated from free iodine by elution through a Dowex anionic exchange column equilibrated with phosphate-buffered saline (PBS) containing 0.3% human serum albumin, as described. The protein-bound radioactive fraction averaged 90%.

Cell line

SK-MES-1, a human squamous cell carcinoma line (American Type Culture Collection HTB 58, 1990), was grown in RPMI-1640 medium (AES, Combourg, France) supplemented with 10% fetal calf serum (Anval, Betton, France), 2 mM glutamine and 80 mg l^{-1} gentamycin, at 37°C in a fully humidified atmosphere of 95% air:5% carbon dioxide. Cells at confluence were trypsinised from monolayer cultures, washed twice in PBS and resuspended in RPMI-1640 before inoculation into mice.

Tumour model

Female athymic mice (nu/nu) (6–8 weeks old) were obtained from Janvier (53590 St Berthevin, France). They were inoculated s.c. (0.1 ml) with 5 × 10^6 SK-MES-1 in the right flank. The tumours reached a 0.6–0.8 cm diameter within 3 weeks after injection. During the experiments, water with potassium iodide (0.2%) was available ad libitum.

Biodistribution studies

Tumour-bearing mice were given injections of 125I-labelled antibodies (6 MBq) in the tail vein. The animals were anaesthetised at various times after i.v. injection, bled and sacrificed. Blood, tumours and organs (lung, spleen, liver, kidney, bone, small bowel, stomach, muscle) were removed, weighed and their radioactivity was counted in a gamma counter (CG 4000 intertechnique). The labelled antibody distributions for blood, tumour and organs were expressed as percentages of the injected dose per gram of tissue (%ID g^{-1}). In some experiments, the results were expressed as μg of radiolabelled Po66 per gram of tissue (μg g^{-1}), a value inferred from %ID g^{-1}. To determine whether blood radioactivity was related to antibody–radioiodine conjugate and not to free iodine, serum samples were precipitated with TCA. About 95% of blood radioactivity was protein bound at each time point.

Histology

The reactivity of MAb with tumour antigens was demonstrated by the immunoperoxidase staining procedure described by Hsu et al. (1981). Briefly, sections were incubated for 2 h with MAb Po66 in 10^{-3} diluted ascites or with normal mouse serum controls, washed with PBS, incubated with biotinylated anti-mouse IgG antibody, washed and exposed to the avidin–biotin–peroxidase complex (vectastain vector). Peroxidase was stained by the diaminobenzidine reaction.

For autoradiographic studies, 5 μm tissue sections were deparaffinised in xylene, dipped in alcohol, rehydrated and processed as follows. The sections were dried and coated with radiographic emulsion (Ilford K5). After 14 days' incubation at 4°C in dehydrated light-tight boxes, the slides were developed in Kodak L × 24 for 5 min, fixed in Ilford Hypam solution and washed. The tissues were then counterstained with haematoxylin–eosin.

Chemotherapy

Doxorubicin (Adriblastin, Farmitalia Carlo Erba, Rueil Malmaison, France) was chosen because it is active on growth of non-small-cell lung carcinoma xenografts (Boven et al., 1992). Two i.v. injections (8 mg kg^{-1}) separated by 7 days were given. The weight loss of mice was only 7% at this dosage regimen.

Statistical analysis

Statistical analysis was performed using Student's unpaired t-test.

Results

Organ distribution of Po66 in the absence of combined doxorubicin treatment

The biodistribution of Po66 was measured in tumour-bearing mice, from 4 h to 14 days after i.v. injection of 50 μg of 125I-radiolabelled Po66 ([125I]Po66). The results, reported in Figure 1, show that Po66 bound to the tumour at 4 h, and then gradually decreased. Py did not bind to the tumour at any time point. The differences in the radioactivity were not significant (p > 0.05).

Figure 1 Organ distribution of 125I-radiolabelled Po66 (a) and 125I-radiolabelled Py (b) injected i.v. on day 0. The results are expressed as a percentage of the injected dose per gram of tissue. Several organ radioactivities were measured (see Table 1), but for simplicity only tumour, blood and lung are shown. Each point represents the mean ± s.d. for five animals. ○, Blood; ●, tumour; □, lung.
Figure 1. Autoradiographs of SK-MES-1 carcinomatous sectioned with 5% formalin, 3 days before sacrifice. (a) Audiocopic view of a ventral section of the tumour. (b) HA-1 stained for human lung tumours. The human tumour cells are shown to be present in almost all tumour cells. (c) Cytokeratin staining of SK-MES-1 lung cancer xenografts (DeSroes et al., 1993).

Table 1  Organ biodistribution of [125]I Po66 in untreated control and doxorubicin-treated tumour-bearing mice

| Tissue       | Day 3<sup>a</sup> |   | Day 5<sup>a</sup> |   | Day 9<sup>a</sup> |   | Day 14<sup>b</sup> |
|--------------|------------------|---|------------------|---|------------------|---|-------------------|
|              | Control          | D - 7/D0 | D0/D + 7 | Control          | D - 7/D0 | D0/D + 7 | Control          | D - 7/D0 | D0/D + 7 |
| Blood        | 10 ± 0.7         | 11.2 ± 0.3 | 8.7 ± 0.4 | 8.5 ± 0.4         | 7.5 ± 0.7 | 9 ± 0.5    | 4.3 ± 0.6    | 4.7 ± 0.7 | 4.9 ± 0.3    | 2.6 ± 0.2 | 2.7 ± 0.7    | 3 ± 0.2    |
| Lung         | 4.5 ± 0.5        | 4.9 ± 0.4 | 3.3 ± 0.2 | 4.5 ± 0.3         | 3.7 ± 0.5 | 4.4 ± 0.39 | 2.1 ± 0.2    | 1.9 ± 0.3 | 1.8 ± 0.2    | 1.1 ± 0.1 | 1.3 ± 0.1    | 1.3 ± 0.1  |
| Spleen       | 2.3 ± 0.2        | 2.4 ± 0.2 | 2.2 ± 0.1 | 2.2 ± 0.4         | 2.3 ± 0.4 | 2.3 ± 16   | 0.9 ± 0.1    | 0.9 ± 0.1 | 1.1 ± 0.1    | 0.6 ± 0.05 | 0.6 ± 0.07  | 0.5 ± 0.07 |
| Liver        | 2.8 ± 0.3        | 2.4 ± 0.3 | 2.6 ± 0.2 | 2.4 ± 0.2         | 2.4 ± 0.19 | 1 ± 0.1    | 1.2 ± 0.2    | 1.2 ± 0.6 | 0.7 ± 0.1    | 0.9 ± 0.1 | 0.8 ± 0.2    |
| Kidney       | 2.9 ± 0.2        | 2.6 ± 0.1 | 2.1 ± 0.1 | 2.6 ± 0.1         | 2.3 ± 0.2 | 2.7 ± 0.28 | 1.2 ± 0.1    | 1.1 ± 0.2 | 1.1 ± 0.6    | 0.6 ± 0.07 | 0.7 ± 0.05  | 0.7 ± 0.05 |
| Bone<sup>b</sup> | 1.3 ± 0.2      | 1.6 ± 0.1 | 1.2 ± 0.03 | 1.1 ± 0.1         | 1 ± 0.1    | 1.1 ± 0.1  | 0.5 ± 0.07   | 0.5 ± 0.08 | 0.7 ± 0.1    | 0.3 ± 0.01 | 0.4 ± 0.05  | 0.3 ± 0.03 |
| Small Bowel  | 1.3 ± 0.1        | 1.2 ± 0.07 | 1.0 ± 0.05 | 1.3 ± 0.07        | 1.2 ± 0.1 | 1.1 ± 0.1  | 0.6 ± 0.06   | 0.5 ± 0.05 | 0.6 ± 0.08   | 0.4 ± 0.03 | 0.5 ± 0.04  | 0.3 ± 0.02 |
| Stomach      | 1.5 ± 0.1        | 1.8 ± 0.1 | 1.4 ± 0.03 | 1.5 ± 0.07        | 1.3 ± 0.1 | 1.5 ± 0.1  | 0.5 ± 0.05   | 0.6 ± 0.03 | 0.6 ± 0.08   | 0.4 ± 0.03 | 0.5 ± 0.04  | 0.3 ± 0.02 |
| Muscle       | 1.1 ± 0.1        | 0.9 ± 0.1 | 0.8 ± 0.05 | 0.9 ± 0.1         | 0.8 ± 0.07 | 0.9 ± 0.1  | 0.4 ± 0.05   | 0.4 ± 0.06 | 0.4 ± 0.03   | 0.3 ± 0.02 | 0.3 ± 0.02  | 0.2 ± 0.01 |
| Tumour       | 6.4 ± 1.3        | 14 ± 2*  | 9.2 ± 1.0 | 7.1 ± 0.8         | 13 ± 1.1* | 11.1 ± 1.3* | 5.2 ± 0.7    | 9.6 ± 2.2 | 11.1 ± 0.6*   | 6.1 ± 0.9 | 6.5 ± 0.8   | 9.2 ± 0.7* |

Data are expressed as mean percentage of injected dose per g of tissue ± s.d. n = 5 10 mice per group. *Days after i.v. injection of [125]I Po66. **One femur. **Significant difference when compared with control group (P < 0.05).
in tumour-bearing nude mice, autoradiographic studies were performed on tumours excised 5 days after injection of $[^{125}]$Po66 or $[^{125}]$Py. As shown in Figure 2a, at low magnification, $[^{125}]$Po66 clearly bound to the central necrotic area of the tumours. At higher magnification (Figure 2b), the label was distributed diffusely in the necrotic area associated with residual anucleated cells or amorphous zones of debris. In $[^{125}]$Py-injected mice (Figure 2c), there was no specific area of binding of radioactivity within the tumour. Thus the autoradiographic investigations showed that $[^{125}]$Po66 preferentially bound to degenerating tumour cells. This was in agreement with a previous demonstration of the intracytoplasmic location of the antigen recognised by Po66 (Martin et al., 1989) and explained why the antigen could only be reached by the MAb when the cell membrane was becoming permeable to macromolecules like immunoglobulins.

As the biodistribution curve of Po66 showed a plateau of accumulation in the tumour between days 3 and 5 and day 14, the effect of a dose escalation of $[^{125}]$Po66 was measured on days 5 and 14. Groups of three or four mice were injected i.v. with increasing amounts of $[^{125}]$Po66 (25, 50, 100 and 200 $\mu$g). As shown in Figure 3, when data were expressed as $\mu$g of Po66 per gram of tissue, a dose-related increase in blood radioactivity was observed. In contrast, tumour radioactivity uptake reached a plateau beyond 100 $\mu$g. These data suggest that above doses of 100 $\mu$g the accessible antigen recognised by Po66 was saturated.

![Figure 3](image1.jpg)

**Figure 3** Tumour and blood radioactivity after injection of various doses of Po66 on day 0. The measurements were made on days 5 (a) and 14 (b) in groups of 3-4 tumour-bearing mice injected i.v. with increasing doses of $[^{125}]$Po66 (25, 50, 100 and 200 $\mu$g). The uptake is expressed as $\mu$g g$^{-1}$ of blood and tumour.

---

**Organ distribution of Po66 combined with doxorubicin treatment**

As Po66 bound to an intracytoplasmic antigen, we attempted to improve its accessibility by combining antibody injection with doxorubicin. Po66 was injected on day 0 and two schedules of administration of doxorubicin were compared. Doxorubicin (8 mg kg$^{-1}$) was injected twice i.v., (1 week interval), either on days -7 and 0 (D-7/D0), or on days 0 and +7 (D0/D+7). Biodistribution was evaluated 3, 5, 9 and 14 days after administration of 50 $\mu$g of $[^{125}]$Po66. As shown in Figure 4, doxorubicin administered twice i.v. (1 week interval) transiently decreased the growth curve of tumours in the time course of the experiments. This difference was not statistically significant, and 14 days after the last injection, the slope of the curve of tumour growth in the doxorubicin-treated group was similar to the slope of the control tumours. The extent of necrosis was determined histologically. In non-treated mice an average of 1-2 areas of necrosis were present in the central part of tumours (15-30% of the section area), although in doxorubicin-treated mice 3-4 areas of more extended necrosis were observed (40-70% of the section area). Figures 2a and 5a are representative of the appearance and the extent of necrosis in control and doxorubicin-treated mice. In the D-7/D0 schedule, however, the necrosis was less extensive on day 14 than on day 5.

Figure 6 shows the % ID g$^{-1}$ of tumour in control and doxorubicin-treated mice. When doxorubicin was administered on day -7 and day 0, a 2-fold increase in $[^{125}]$Po66 uptake (compare controls) was observed in tumours on days 3 and 5 (13.9±2 and 13.1±1.1% ID g$^{-1}$ respectively, $P<0.05$). Tumour uptake was still elevated on day 9, but did not differ significantly from the control, and returned to control values on day 14. When doxorubicin was administered on day 0 and day +7, a statistically significant increase in tumour uptake was observed on days 5 and 9. This uptake remained elevated on day 14 (9.2±0.7% ID g$^{-1}$ vs 6.1±0.9% ID g$^{-1}$ for control; $P=0.05$). Doxorubicin did not interfere with the uptake of Po66 by normal tissues (Table 1). Po66 binding to tumours was dependent on the dose of doxorubicin injected and no increased radioactivity binding to tumours was observed with 4 mg kg$^{-1}$ doxorubicin (6.4±1.4 and 5.8±0.6% ID g$^{-1}$ of tumour on days 5 and 14 respectively, for the D0/D+7 schedule, $n=3$ mice).

![Figure 4](image2.jpg)

**Figure 4** Growth curve of untreated and doxorubicin-treated tumours. Doxorubicin (8 mg kg$^{-1}$) was injected i.v. on days -7 and 7 (arrows). Tumour growth was monitored by measuring the long and short axis for each tumour ($n=5$) (twice weekly and calculating the tumour volume as (cm, short axis)$^2$ x (cm, long axis)/2). O, Control; D, doxorubicin.
Autohistoautoradiographic analysis was performed on tumours removed from mice pretreated with doxorubicin (D = 7 D0) and sacrificed 5 days after i.v. injection of $^{[25]}$I Po66. Figure 5a clearly shows, at low magnification, that in contrast to controls (Figure 2a), treatment with doxorubicin induced numerous necrotic areas that bound silver grains. At higher magnification (Figure 5b), in areas adjacent to necrosis, many spots of silver grain were observed, and were probably related to the binding of $^{[25]}$I Po66 to degenerating cells. Necrosis was, therefore, accompanied by a more homogeneous distribution of radioiodinated Po66 in tumours.

As reported above (Figure 3), the uptake of radioiodinated Po66 by the tumour reached a plateau for an injection of above 100 μg MAb per mouse. This plateau was examined in doxorubicin-treated mice. The administration of doxorubicin significantly increased the tumour uptake of 200 μg of $^{[25]}$I Po66 on day 5, particularly when doxorubicin was administered before Po66 (D = 7 D0; Figure 7). On day 14, according to previous observations, the tumour uptake was higher when doxorubicin was administered with the D0 D + 7 schedule. This phenomenon is probably due to the fact that more antigenic sites were accessible after doxorubicin treatment.

**Discussion**

Po66, like other MAbs directed against intracellular antigens (Epstein et al., 1988), binds predominantly to necrotic areas of tumours. This is probably because of the ability of the MAb to cross damaged cytoplasmic membranes. The most important problem raised by such antibodies is that they cannot reach their target in viable cells. Also, the access of the MAb to the necrotic zones may be difficult, owing to unfavourable physicochemical conditions in the central parts of bulky tumours with poor vasculature, and altered pH and hydrostatic pressure (Jain, 1990). Another limitation for these MAbs is that the amount of accessible antigen depends on the degree of necrosis, which is variable and unpredictable.

MAbs directed against internal antigens may have, however, several advantages. First, the intracytoplasmic localisation offers a double binding specificity: antigen–antibody interaction, and access to antigen only in damaged tumour cells, a specific pattern of tumours, even at an early stage of development (Cooper et al., 1975). Such MAbs cannot bind
to normal tissues even if these tissues express the antigen. Second, the 'binding site barrier' effect described by Weinstein et al. (1992) does not seem to apply to intracellular antigens. This effect consists of a limitation of antibody penetration in tumours due to a preferential uptake by easily accessible antigen sites of tumour nodules. We demonstrated here with Po66 that the MAB penetrated the central necrotic cores of the tumours. This was to be expected from in vitro models which showed good diffusion of MABs through three-dimensional culture systems (Carlsson et al., 1989; Dazord et al., 1993). Third, another important advantage of anti-internal antigen antibodies is their prolonged retention time in the tumours (Welt et al., 1987). Po66 was still detected at high levels in the tumour up to 14 days post injection. In man, Po66 was also found to persist for a long time (Bourguet et al., 1990). This situation is very favourable for the two-step therapies described in the introduction. Fourth, as shown here with Po66, it was possible to enhance tumour uptake of the MAB by means of chemotherapy. This correlated with the induction of necrosis as observed histologically. However, it remains possible that doxorubicin treatment increases tumour blood flow by dilating vessels near the necrotic areas, thus leading to increased antibody delivery, as has been shown with radiation and hyperthermia (Stuckey et al., 1987). In the D - 7/T0 protocol, the uptake of Po66 was more elevated than in controls on days 3 and 5, but idoxorubicin-induced 14. This is probably due to a repopulation of the tumour by new dividing cells, 2 and 3 weeks after treatment with doxorubicin, as would be expected from the growth curve. When doxorubicin was administered on days 0 and 7, high uptake on days 9 and 14 was observed, suggesting that this protocol of doxorubicin administration maintained necrosis within tumours and probably allowed more persistent access to the antigen by Po66 rather than doxorubicin-induced 14. This is probably due to a repopulation of the MAB in new necrotic areas. This suggests that for an optimal effect, chemotherapy and radiolabelled MAB should be separated by a relatively short interval.

In terms of radiolabelled MABs as potential tools in cancer treatment, the present investigation in a mouse model leads to some speculations. As shown in Figure 2a, it is possible that a medium-range radioisotope like iodine-131 would not reach and destroy distant viable cells at the edge of the tumour. However, sequential injection of radiolabelled antibody could produce an ever expanding population of new target cells in the tumour as a result of the centrifugal killing of adjacent viable tumour cells, as has been shown previously with an antibody directed against an intracellular antigen (Chen et al., 1989). However, the combination of chemotherapy with radiolabelled MABs directed against a cytoplasmic antigen might produce a synergistic effect. Improved diffusion of the MAB throughout the tumour may result in the irradiation of the last drug-resistant cells, by a cross-fire effect from all necrotic areas induced by chemotherapy. The treatment would be particularly beneficial for small scattered metastases. The question arises whether the combination of both drugs would also enhance bone marrow toxicity. It is important to note that the antigen recognised by Po66 is not present in haematopoietic cells (Dazord et al., 1987), and not the lysis of these cells by the associated chemotherapy would not sensitize them to irradiation as intensely as tumour cells. In contrast, MABs directed against ubiquitous intracellular antigens like histones (Epstein et al., 1988) could have such an effect.

On the other hand, it is likely that the non-specific irradiation due to circulating radiolabelled MAB, combined with chemotherapy, would prove toxic for haematopoietic bone stem cells. Although bone marrow support has been proposed in immunoradiotherapy protocols (Press et al., 1993), it would be preferable to minimise this non-specific toxicity. This could be done by using Po66 as the first part of a two-step treatment. The principles of this technique were outlined in the introduction. Po66 is a particularly good candidate for such use. Its retention in tumours is prolonged, even if the MAB fraction remaining in the circulation is artificially reduced (Desrues et al., 1995).

Cancer treatment with radiolabelled MABs raises important problems of dosimetry. In the mathematical formulae for the calculation of the radiation dose, it is usually assumed that the irradiation source is uniformly distributed in the tissue, which is obviously not the case for MABs (Zalberg et al., 1981; Badger et al., 1986). Microscopic dosimetry seems more appropriate for MABs (Humm et al., 1990), but is difficult to compute. Consequently, to appreciate the additive effect of immunoradiotherapy and chemotherapy, animal models such as that described here seem more suitable than theoretical and in vitro investigations. Treatment of lung cancer in the mouse model described in the present work by combining chemotherapy and tumoricidal doses of [111Ir]Po66 is currently under investigation in our laboratory.

Acknowledgements

This work was supported by the Association pour la Recherche sur le Cancer (ARC) and the Comités Départementaux Contre les Maladies Respiratoires et la Tuberculose. We gratefully acknowledge the technical assistance of J-C Rimbert and H Merritte.

References

BADGER CC, KROHN KA, SHULMAN H, FLOURNOY N AND BERNSTEIN I. (1986). Experimental radioimmunotherapy of murine lymphoma with [111In]-labelled anti-T cell antibodies. Cancer Res., 46, 6222–6228.
BLUMENTHAL RD, SHARKEY RM, SNYDER D AND GOLDENBERG DM. (1988). Reduction by anti-antibody administration of the radioactivity associated with [111In]-labelled antibody to carcinoembryonic antigen in cancer radioimmunotherapy. J. Nal Cancer Inst., 81, 194–199.
BOSSELLET K, STEINTRAESSER A, HERMENTIN P, KUHLMANN L, BRUYNCK A, MAGERSTAEDT M, SEEMANN G, SCHWAB A AND SEDLACEK HH. (1991). Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy. Br. J. Cancer, 63, 681–686.
BOURGUET P, DAZORD L, DESRUES B, PELLEN P, COLLET B, RAMÈE M-P, DELVAL PH, MARTIN A, LOGEAIS Y, PELLETIER A, TOUJAS L, BOUREL D, KERNEC J, SACCAVINI JP, KREMER M AND HERRY JY. (1990). Immunocytographic detection of squamous cell carcinoma with a iodine 131-labeled monoclonal antibody. Br. J. Cancer, 61, 230–234.

BOVEN E, WINOGRAD B, BERGER DP, DUMONT MP, BRAAKHUIS BJM, FODSTAD O, LANGDON S AND FIEBIG HH. (1992). Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res., 52, 5940–5947.
BUCHEGGER F, PFISTER C, FOURNIER K, PREVEL F, SCHREYER M, CARREL S AND MACH JP. (1989). Ablation of human colon carcinoma in nude mice by [111In]-labelled monoclonal anti-carcinoembryonic antigen antibody F(ab')2, fragments. J. Clin. Invest., 83, 1449–1456.
BUSCHBAUM DJ, BRUBAKER PG, HANNA DE, GALTREFTER AA, TERRY VH, GUILBAULT DM AND STEPLEWSKI Z. (1990). Comparative binding and preclinical localization and therapy studies with radiolabelled human chimeric and murine 17-1A monoclonal antibodies. Cancer Res., 50, 9939–999.
CARLSSON J, DANIEL-SZOLGAY E, FRYKHLOM G, GLIMIELIUS B, HEDIN A AND LARSSON B. (1989). Homogenous penetration but heterogeneous binding of antibodies to carcinoembryonic antigen in human colon carcinoma HT-29 spheroids. Cancer Immunol. Immunother., 30, 269–276.
LEBERTHON B, KHAWLI LA, ALAUDIN M, MILLER GK, CHARAK BS, MAZUMDER A AND EPSTEIN AL (1991). Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunconjugate. Cancer Res., 51, 2694–2698.

LE DOUSSAL JM, MARTIN M, GAUTHEROT E, DELAGE M AND BARTLET J (1989). In vitro and in vivo targeting of radiolabeled monovalent and divalent haptons with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J. Nucl. Med., 30, 1358–1366.

MARTIN A, PELLEN P, GUITTON C, YOUNOU P, COLLET B, DESRUES B, BOUREL D, DAZORD L AND TOUJAS L (1989). Characterization of the antigen identified by Po66. Cancer Immunol. Immunother., 29, 118–124.

NAKAMURA K AND KUBO A (1994). Effect of interleukin-2 on the biodistribution of technetium-99m-labelled anti-CEA monoclonal antibody in mice bearing human tumour xenografts. Eur. J. Nucl. Med., 21, 924–929.

PRESS O, EARY JF, APPELBAUM FR, MARTIN PJ, BADGER CC, NELP WB, GLENN S, BUTCHKO G, FISHER D, PORTER B, MATTHEWS DC, FISHER LD AND BERNSTEIN ID. (1993). Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329, 1219–1224.

REYNOLDS JC, DEL VECCIO S, SAKAHARA H, LORA ME, CARRASQUILLO JA, NEUMANN RD AND LARSON SM (1989). Antimurine antibody response to mouse monoclonal antibodies: clinical findings and implications. Nucl. Med. Biol., 16, 121–125.

ROSENBLUM MG, LAMKI LM, MURRAY JL, CARLSTEW D AND GUTERMAN J. (1988). Interferon-induced changes in pharmacokinetics and tumor uptake of 111In-labelled antimelanoma antibody 96.5 in melanoma patients. J. Natl Cancer Inst., 80, 160–165.

SCHLOM J, EGGENSPERGER D, COLCHER D, MOLINO AL, HOUCHENS D, MILLER LS, HINKLE G AND SILER K. (1992). Therapeutic advantage of high-affinity ant carcinoemia radioimmunoconjugates. Cancer Biother. Radiopharm., 7, 1061–1070.

SHARKEY RM, MOTTA-HENNESSY C, PAWLKY D, SIEGEL JA AND GOLDENBERG DM (1990). Biodistribution and radiation dose estimates for yttrium- and iodine-labelled monoclonal antibody IgG and fragments in nude mice bearing human colon tumor xenografts. Cancer Res., 50, 2330–2336.

STICKNEY DR, GRIDLEY DS, KIRK GA AND SLATER JM. (1987). Enhancement of monoclonal antibody binding to melanoma with single dose radiation or hyperthermia. NCI Monographs, 3, 47–52.

WEINSTEIN JN AND VAN OSDOL W. (1992). Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the ‘binding site barrier’. Cancer Res., 52, 2747s–2751s.

WELT S, MATTES MJ, GRANDO R, THOMSON TM, LEONARD RW, ZANONICO PB, BIGLER RE, YEH S, GETTGEN HF AND OLD LJ. (1987). Monoclonal antibody to an intracellular antigen images human melanoma transplants in nude mice. Proc. Natl Acad. Sci. U.S.A., 84, 4200–4204.

ZALCBERG JR, THOMPSON CH, LICHTENSTEIN M AND MCKENCIES IF. (1981). Tumor immunotherapy in the mouse with the use of 111I-labelled monoclonal antibodies. J. Natl Cancer Inst., 72, 697–704.